Society of Neuro-Oncology (SNO)
27^th Annual Scientific Meeting and Education Day in Tampa, Fla. (Nov. 16-20, 2022)

• McDonald MF, Prather LL, Helfer CR, Ludmir EB, Echeverria AE, Patel AJ, et al. Pathogenic germline mutations in glioma patients. Presented at the Society of Neuro-Oncology (SNO), 27^th Annual Scientific Meeting and Education Day in Tampa, Fla. (Nov. 16-20, 2022).  

Society of Neuro-Oncology (SNO)
26^th Annual Scientific Meeting and Education Day in Boston, Mass. (Nov. 18-21, 2021)

• Rogers J, Acquaye A, Ikiddeh-Barnes U, Benson K, Boris L, Akindona F, et al. An innovative virtual multi-institutional, multidisciplinary neuro-oncology tumor board: The NIH-NOB experience during the COVID-19 pandemic. Neuro Oncol. 2021;23(Suppl 6):111. 

Society of Neuro-Oncology (SNO)
25^th Virtual Annual Scientific Meeting and Education Day (Nov. 19-21, 2020)

• Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Ludmir E, et al. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. Neuro Oncol. 2020;22(Suppl 2):125. 

American Academy of Neurology (AAN)
72^nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)

• Mandel J, Youssef M, Ludmir E, Patel A, Jalali A, Treiber J, et al. Treatment strategies for glioblastoma in older patients: Age is just a number. Neurology. 2020;94(15 Suppl):2612. 
• Mandel J, Youssef M, Yust-Katz S, Patel A, Jalali A, Wu J, et al. Examining the impact of isocitrate dehydrogenase (IDH) gene status on the development of venous thromboembolism in glioma patients. Neurology. 2020;94(15 Suppl):2651. 

Society of Neuro-Oncology (SNO)
23^rd Annual Scientific Meeting and Education Day in New Orleans, La. (Nov. 15-18, 2018)

• Mandel J, Youssef M, Nam J, Patel A, Liu D, Wu J, et al. Effect of health disparities on overall survival of patients with glioblastoma. Neuro Oncol. 2018;20(Suppl 6):81. 

American Society of Clinical Oncology (ASCO)
54^th Annual Meeting in Chicago, Ill. (June 1-5, 2018)

• De Groot JF, Penas-Prado M, Mandel JJ, O'Brien BJ, Weathers S-PS, Zhou S, et al. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. Presented at the American Society of Clinical Oncology (ASCO), 54^th Annual Meeting in Chicago, Ill. (June 1-5, 2018).  

American Academy of Neurology (AAN)
70^th Annual Meeting in Los Angeles, Calif. (April 21-27, 2018)

• Mandel J, Youssef M, Nam JY, Wu J, Liu DD, Bondy M, et al. Effect of health disparities on overall survival of patients with glioblastoma. Neurology. 2018;90(15 Suppl):P6.157.  [View poster]
• Nascimento F, Kan P, Sharp L, Mandel J. Spinal dural arteriovenous fistula and concomitant intramedullary spinal lesion. Neurology. 2018;90(15 Suppl):P6.122.  [View poster]
• Yuan D, Nascimento F, Woc-Colburn L, Foroozan R, Mandel J. Vision impairment and papilledema as the initial manifestation of neurosyphilis in a young immunocompetent patient. Neurology. 2018;90(15 Suppl):P5.130.  [View poster]

American Academy of Neurology (AAN)
68^th Annual Meeting in Vancouver, BC, Canada (April 15-21, 2016)

• Mandel J, Cachia D, Liu DD, Aldape K, Fuller G, De Groot J. Impact of IDH-1 mutation status on outcome in clinical trials for recurrent glioblastoma. Neurology. 2016;86(Meeting Abstracts 1):P5.255. 

American Society of Clinical Oncology (ASCO)
51^st Annual Meeting in Chicago, Ill. (May 29 - June 2, 2015)

• Mandel JJ, Cachia D, Liu DD, Aldape KD, Fuller G, De Groot JF. IDH1 mutation status and outcome in clinical trials for recurrent glioblastoma. J Clin Oncol 33, 2015 (suppl; abstr 2073)  [View poster]

American Society of Clinical Oncology (ASCO)
50^th Annual Meeting in Chicago, Ill. (May 30 - June 3, 2014)

• Pawar T, Ladha H, Mandel J, Gilbert M, O'Brien B, Hamza M, et al. Adverse effects of bevacizumab in brain tumor patients. Neuro Oncol. 2014;16(suppl 5):v49. 
• Yust-Katz S, Mandel J, Ying Y, Wu J, Courtney C, Ladha H, et al. Venous thromboembolism (VTE) and glioblastoma. Neuro Oncol. 2014;16(suppl 5):v212. 

American Academy of Neurology (AAN)
66^th Annual Meeting in Philadelphia, Penn. (April 26 - May 3, 2014)

• Mandel J, Webre CC, Shonka NA, Yung WK, De Groot J. Improved progression free survival in 1p/19q co-deleted anaplastic oligodendroglioma treated with both chemotherapy and radiation therapy at diagnosis. Neurology. 2014;82(Meeting Abstracts 1):S22.006. [Platform Presentation] 

Society of Neuro-Oncology (SNO)
18^th Annual Meeting in San Francisco, Calif. (Nov. 21-24, 2013)

• Hamza M, O'Brien B, Mandel J, de Groot J. Survival outcomes of patients with recurrent anaplastic glioma treated with bevacizumab. Neuro Oncol. 2013;15(suppl 3):iii110-1. 
• Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M. Glioblastoma and leptomeningeal dissemination. Neuro Oncol. 2013;15(suppl 3):iii119-20. 

European Neurological Society (ENS)
23^rd Annual Meeting in Barcelona, Spain (June 8-11, 2013)

• Mandel J, Tremont-Lukats I, Tummala S. Tosedostat and posterior reversible encephalopathy syndrome (PRES). J Neurol. 2013;260 (suppl 1):S25-6. [Oral Presentation] 
• Mandel J, Woodman K, Tummala S, Tremont-Lukats I. Severe neurological disability in cancer patients acutely infected with the West Nile virus (WNV). J Neurol. 2013;260 (suppl 1):S171. 

American Society of Clinical Oncology (ASCO)
49^th Annual Meeting in Chicago, Ill. (May 31 - June 4, 2013)

• Hamza MA, Mandel J, Conrad CA, Gilbert MR, Yung WKA, Puduvalli VK, et al. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(May 20 suppl):2042. 

American Academy of Neurology (AAN)
64^th Annual Meeting in New Orleans, La. (April 21-28, 2012)

• Mandel J, Oas J. Sporadic CJD (VV2 Type) presenting with central vestibular abnormalities. Neurology. 2012;78(Meeting Abstracts 1):P03.259. 
• Mandel J, Quick A, Lawson V. Early predictors of progression in idiopathic sensory neuropathy. Neurology. 2012;78(Meeting Abstracts 1):P03.209.